Search filters

List of works by Danelle F James

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️

scientific article

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

scientific article published on 05 June 2018

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

scientific article published on 10 January 2017

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

scientific article

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

scientific article

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

scientific article

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

scientific article

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

scientific article

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

scientific article published on 06 March 2019

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

scientific article published on 8 January 2015

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

scientific article published on 22 February 2018

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

scientific article published on 10 January 2014

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

scientific article

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

scientific article

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

scientific article published on 2 February 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

scientific article (publication date: 4 July 2013)

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

scientific article published on 28 February 2015

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

scientific article

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

scientific article published on 10 February 2019

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Scientific article published on 2 Dec 2016

Paulina is supported by:

About Paulina

Help